NVCT Nuvectis Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVCT

Price (delayed)

$9.63

Market cap

$255.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$230.31M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock ...

Highlights
The net income has contracted by 35% YoY and by 2.7% from the previous quarter
The equity has contracted by 32% YoY and by 23% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.nuvectis.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of NVCT

NVCT stock price

How has the Nuvectis Pharma stock price performed over time
Intraday
3.44%
1 week
-5.5%
1 month
8.32%
1 year
8.69%
YTD
27.55%
QTD
24.58%

Financial performance

How have Nuvectis Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.27M
Net income
-$27.16M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 35% YoY and by 2.7% from the previous quarter
The operating income has declined by 34% year-on-year and by 2.5% since the previous quarter

Price vs fundamentals

How does NVCT's price correlate with its fundamentals

Growth

What is Nuvectis Pharma's growth rate over time

Valuation

What is Nuvectis Pharma stock price valuation
P/E
N/A
P/B
17.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVCT's EPS is down by 16% year-on-year
NVCT's P/B is 67% higher than its last 4 quarters average of 10.4 and 65% higher than its 5-year quarterly average of 10.5
The equity has contracted by 32% YoY and by 23% from the previous quarter

Efficiency

How efficient is Nuvectis Pharma business performance
The ROE has contracted by 12% from the previous quarter and by 8% YoY
The ROA has decreased by 7% QoQ and by 3.5% YoY

Dividends

What is NVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCT.

Financial health

How did Nuvectis Pharma financials performed over time
Nuvectis Pharma's total assets is 127% more than its total liabilities
Nuvectis Pharma's current ratio has decreased by 31% YoY and by 4.6% from the previous quarter
NVCT's quick ratio is down by 31% year-on-year and by 5% since the previous quarter
NVCT's debt is 100% lower than its equity
The equity has contracted by 32% YoY and by 23% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.